PLATFORM Study of Precision Medicine for Rare Tumors

Phase 2

Recruiting

• Conditions: Rare Tumor
• Interventions: Drug: Almonertinib 110 MG; Drug: Dacomitinib 45 MG; Drug: Alectinib 150 MG; Drug: Crizotinib 250 MG; Drug: Pyrotinib 160/80 MG; Drug: Palbociclib 125mg; Drug: Vemurafenib 240 MG; Drug: Sintilimab 100MG; Drug: Niraparib 200/300 MG; Drug: Imatinib 400 MG; Drug: Atezolizumab 1680 MG

• Registration Number: NCT04423185
• Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Brief Summary

A Phase II, open label, non-randomized, multiple-arm, single-center clinical trial in patients with advanced rare solid tumors who failed to standard treatment.

Detailed Description

Based on the fact that a high incidence rate (14.2%) of rare tumor (incidence rate \<2.5/100,000) as defined in this study according to the National Cancer Registry data from National Cancer Center of China, as well as the current status of lacking guidelines and consensus of rare tumor treatment. We proposed this study "A Phase II, open label, non-randomized, multiple-arm, single-center clinical trial in patients with advanced rare solid tumors who failed to standard treatment", aims to evaluate the safety and efficacy of targeted drugs of specific tumor-driven genes in patients with advanced rare solid tumors with corresponding actionable alterations, as well as the safety and efficacy of immune checkpoint (PD-1) inhibitors in patients with advanced rare solid tumors without actionable alterations. Patients with advanced rare tumors who failed to standardized treatment carrying actionable alterations as "EGFR mutation (exon 19 deletion mutation, L858R replacement mutation), ALK gene fusion, ROS-1 gene fusion, C-MET gene amplification or mutation (D1010 mutation, 14 exon mutation, y1003 mutation), BRAF mutation, CDKN2A mutation, BRCA1/2 mutation, HER-2 mutation, HER-2 over expression/amplification, C-KIT mutation", will enroll targeted therapy arms and be given corresponding targeted drugs (Dacomitinib, Crizotinib). And patients without targeted alterations mentioned above will enroll PD-1 inhibitor arm and to be treated with Sintilimab. After acquired resistance patients treated with olaparib and palbociclib will receive combination treatment with durvalumab. After acquired resistance patients treated with vemurafenib will receive combination treatment with atezolizumab. The statistics of current study adopts Simon's two-stage Minimax design: In the first stage of clinical research, 12 subjects will be observed. If the number of CR + PR is less than 1, the trial will be terminated, otherwise, the group will continue to expand to 16 subjects. Therefore, in the first stage, there are 12\*5/(1-10%)=54 patients of targeted treatment group and 126 patients in the immunotherapy group, 180 patients totally in the first stage. If they all enter the second stage, the final target treatment group is 16\*5/(1-10%) = 72 patients and the immunotherapy group which has 168 patients which brings to a total of 240 patients. The sample size of the study shall be adjusted according to the interim analysis. Primary Endpoint of this study is objective response rate (ORR) in immunotherapy group and targeted therapy group assessed by Blinded Independent Central Review (BICR) and investigator. Secondary Endpoints are Progression-Free Survival (PFS) in the targeted treatment group assessed by Blinded Independent Central Review and investigator; PFS (RECIST 1.1) and iPFS (iRECIST) in the single drug immunotherapy group assessed by Blinded Independent Central Review and investigator; Duration of Response (DoR) in the targeted therapy and single immunotherapy groups assessed by the investigator; Durable Clinical Benefit (DCB) in the single drug immunotherapy group; Incidence of Adverse Events (AE) in subjects ect.

Study Timeline

• Study First Submitted: 2020-05-27
• Study First Submitted QC: 2020-06-08
• Study First Posted: 2020-06-09
• Study Start: 2020-08-15
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-08
• Last Update Posted: 2025-02-11
• Primary Completion: 2026-07-01
• Study Completion: 2028-07-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 770

Inclusion Criteria

1. Male or female, the age at the time of signing the informed consent is no less than 18 years old;
2. Patients with advanced or metastatic rare solid tumor confirmed by histological confirmed;
3. ECOG score is 0 or 1; ECOG score needs to be evaluated 7 days before the first treatment;
4. Expected survival ≥12 weeks;
5. According to Response Evaluation Criteria in Solid Tumor (RECIST 1.1), there is at least one imaging measurable lesions, which has obvious disease progress before radiotherapy or after radiotherapy;
6. Within the scope of CMPA approved drug indications, the disease has progressed after the standard treatment recommended by NCCN or CSCO guidelines (if there is standard treatment, the recommended level is IA-IIA), or there is no standard effective treatment plan, or it is no longer suitable for standard anti-tumor treatment, or the patients refuse the standard treatment plan;
7. Fresh biopsy tissue samples (obtained within 12 weeks before the first use of the drug, 4 pieces of coarse needle biopsy must be provided, and no other anti-tumor treatment, systemic anti infection treatment, vaccination, et al.) and peripheral blood samples must be provided for molecular typing;
8. Must have a primary or metastatic paraffin specimen (without radiotherapy) other than bone metastatic lesions before enrollment (within 2 years, 15-20 sheets, 4-6μm thick white slices, of which 5 need to be glued and baked ). If requirements are not met, investigator are allowed the decision to enroll subjects according to the specific situation.
9. If there is pleural or peritoneal effusion, the specimens must be taken for pathological cytological examination of which 300 ml samples must be provided;
10. In the condition that the primary lesions biopsy specimen has been provided, if the metastatic lesion is able to be biopsied, it is suggested to keep the specimen for pathological testing and provide fresh tissue specimen (optional); when obtaining EGFR mutation, ALK fusion, ROS-1 fusion, C-MET amplification, C-MET mutation, BRAF mutation, BRCA1/2 mutation, C-KIT mutation, HER-2 mutation HER-2 over expression/amplification, CDKN2A mutation patients will enroll in corresponding sub-study of targeted therapy; if no above mentioned actionable mutation is identified, patients will enroll immunotherapy sub-study. (Each sub-study has separate inclusion and exclusion criteria besides general ones)
11. After the progression of the subject's disease, if conditions permit, fresh tissue samples shall be obtained from the same biopsy lesions and the metastasis lesions of the previously obtained samples;
12. Toxic and side effects caused by previous treatment need to be restored to ≤ Grade 1 or returned to the baseline value (NCI-CTCAE version 5.0, except for hair loss);
13. Negative pregnancy test (only applicable for women with childbearing potential). No childbearing potential is defined as being postmenopausal for longer than one year or having undergone surgical sterilization or hysterectomy. All patients (male and female) agree to use an effective form of contraceptive measures and continue its use for the duration of treatment and within 8 weeks after the end of treatment;
14. Signed, written informed consent of volunteers that join the group shall follow the study treatment plan, follow-up plan and cooperate to observe the adverse events and efficacy.

Exclusion Criteria

1. History of PD-1 / PD-L1 drug treatment.

2. History of the targeted drug treatment of this study.

3. Allergies towards drug ingredients or excipients in this study.

4. History of interstitial lung disease or radiation pneumonitis of any type.

5. Central Nervous System (CNS) metastases with brain metastases-related symptoms, which is not stable in neurology, or need to increase steroid dosage to control CNS disease. (Note: Patients with controlled CNS metastasis are eligible to participate in this study. Before entering the study, subject must have completed radiotherapy or CNS tumor metastasis surgery for more than fourteen days, neurological function must be in a stable state with no new neurological defects found in the clinical examination and no new problems found in the CNS imaging examination. If necessity arises for subjects to use steroids for CNS metastases treatment, said steroid treatment dose must have reached stable treatment for ≥ 3 months at least two weeks before entering the study.

6. Current uncontrollable third cavity effusion, such as a large amount of pleural effusion or ascites.

7. Unmeet the inclusion criteria of sub scheme.

8. Major surgical operations or incomplete healing of injury within 28 days prior to study treatment's first administration and chest radiotherapy of > 30 Gy within 6 months.

9. History of receiving other investigational drugs within 14 days or 5 half-lives (whichever is longer) prior to the first administration.

10. History of receiving live vaccine within 30 days prior to the first administration. Seasonal influenza vaccines that do not contain live viruses are allowed.

11. History of hypersensitivity to the active ingredients or non-active excipients of the study drug, hypersensitivity to drugs with chemical structure similar to the study drug or hypersensitivity to similar drugs of the study drug.

12. Current active infection requiring systemic treatment (antibiotics); or any of the following:

    1. HIV positive or known history of acquired immunodeficiency syndrome;
    2. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection is defined as HBsAg positive and the number of HBV DNA copies exceeds the upper limit of normal value, or HCV AB positive;
    3. Active tuberculosis (with exposure history or positive tuberculosis test; with clinical and / or imaging manifestations);
    4. Positive antibody of Treponema Pallidum.

13. Current evidenced uncontrollable systemic diseases (such as severe mental, neurological, epilepsy or dementia, unstable or uncompensated respiratory, cardiovascular, liver or kidney diseases, uncontrolled hypertension [i.e., still greater than or equal to CTCAE Grade 3 hypertension after drug treatment]).

14. History of myocardial infarction, coronary artery / peripheral artery bypass or cerebrovascular accident within 3 months.

15. Diagnosed with a second type of malignant tumor within 5 years before the first diagnosis of a rare solid tumor (excluding completely resected basal cell carcinoma, bladder carcinoma in situ, cervical carcinoma in situ).

16. History of receiving of any organ transplantation, including allogeneic stem cell transplantation. Transplantation without immunosuppression (corneal transplantation, hair transplantation) is excluded.

17. Cardiovascular disease or symptom includes any of the following:

    1. History of Congestive Heart Failure requiring treatment and of New York Heart Association class III / IV CHF (see Appendix 3) ;
    2. Current ventricular arrhythmia requiring antiarrhythmic drugs treatment, or uncontrollable or unstable arrhythmia;
    3. Severe conduction disorder (such as grade II or III AV block);
    4. Angina requiring treatment;
    5. QT interval (QTC) of 12 lead ECG is ≥ 450 ms in male and ≥ 470 MS in female;
    6. History of congenital long QT syndrome, congenital short QT syndrome, torsade de pointe or pre-excitation syndrome;
    7. History of LVEF decline to below 50% determined by echocardiography or MUGA scan;
    8. History of myocardial infarction in the past 6 months.

18. Inadequate bone marrow reserve or organ function evidenced by the following laboratory results:

    1. Absolute value of neutrophils < 1.5 × 109 / L;
    2. Platelet count < 100 × 109 / L (transfusion dependent patients should be excluded from this study);
    3. Hemoglobin < 90g / L;
    4. ALT is > 2.5 x Upper Limit of Normal (ULN) If there is no clear liver metastases, ALT > 5 x ULN if there is liver metastases;
    5. Aspartate aminotransferase (AST) > 2.5 x ULN If there is no definite liver metastases. AST > 5x ULN if there is liver metastases;
    6. Total bilirubin > 1.5 x ULN if there is no liver metastases; Total bilirubin > 3 x ULN if there is definite Gilbert syndrome (Unconjugated Hyperbilirubinemia) or liver metastases;
    7. Creatinine > 1.5 x ULN with Creatinine clearance < 50 ml / min (measured value, or calculated value by Cockcroft Gault formula); Only when Creatinine > 1.5 x ULN, Creatinine clearance needs to be checked for confirmation;
    8. If bone metastasis is present and investigator concluded that liver function is adequate, the increase of ALP alone will not be excluded;
    9. Coagulation function: INR, PT, APTT> 1.5 times ULN (whether the patients using or not using anticoagulant drugs can be enrolled is determined by the investigator).
    10. Myocardial enzyme CK and CKMB test values are not in the normal range;
    11. The examination value of thyroid function is not within the normal range or it is not slightly abnormal but does not need treatment.

19. History of swallowing dysfunction, active gastrointestinal disease or other diseases that significantly affect the absorption, distribution, metabolism and excretion of oral drugs. The patients with history of subtotal gastrectomy. (Note: this standard is not applicable to the sub schemes with the investigational drug as injection).

20. Pregnant or lactating women.

21. Serious medical or mental illness that may affect program compliance and tolerance to treatment.

22. Those investigators believe that patients with other potential risks are not suitable for this study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Combination ARM-Vemurafenib & Atezolizumab	Atezolizumab 1680 MG	Vemurafenib (960 mg oral bid) \& Atezolizumab (1200mg iv q21d) after acquired resistance to Vemurafenib.
Almonertinib-EGFR mutation	Almonertinib 110 MG	Administration: 110 mg oral qd, to disease progression or intolerable adverse effects.
Combination ARM-Palbociclib & Atezolizumab	Atezolizumab 1680 MG	Palbociclib (125 mg oral qd for 21 days q28d) combined with Atezolizumab (1680mg iv q28d) after acquired resistance to Palbociclib.
Dacomitinib-EGFR mutation	Dacomitinib 45 MG	Administration: 45 mg oral qd, to disease progression or intolerable adverse effects.
Alectinib-ALK fusion	Alectinib 150 MG	Administration: 600 mg oral qd, to disease progression or intolerable adverse effects.
Crizotinib-ALK fusion	Crizotinib 250 MG	Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
Crizotinib-C-MET amplification	Crizotinib 250 MG	Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
Pyrotinib-HER-2 overexpression/amplification	Pyrotinib 160/80 MG	Administration: 400 mg oral qd, to disease progression or intolerable adverse effects.
Pyrotinib-HER-2 mutation	Pyrotinib 160/80 MG	Administration: 400 mg oral qd, to disease progression or intolerable adverse effects.
Palbociclib-CDKN2A mutation	Palbociclib 125mg	Administration: 125 mg oral qd for 21 days q28d, to disease progression or intolerable adverse effects.
Combination ARM-Palbociclib & Atezolizumab	Palbociclib 125mg	Palbociclib (125 mg oral qd for 21 days q28d) combined with Atezolizumab (1680mg iv q28d) after acquired resistance to Palbociclib.
Combination ARM-Vemurafenib & Atezolizumab	Vemurafenib 240 MG	Vemurafenib (960 mg oral bid) \& Atezolizumab (1200mg iv q21d) after acquired resistance to Vemurafenib.
Sintilimab-PD-1	Sintilimab 100MG	Administration: 200mg q21d, to disease progression or intolerable adverse effects.
Vemurafenib-BRAF mutation	Vemurafenib 240 MG	Administration: 960 mg oral bid, to disease progression or intolerable adverse effects.
Niraparib-BRCA mutation or HRD	Niraparib 200/300 MG	Administration: 200/300 mg oral qd, to disease progression or intolerable adverse effects.
Crizotinib-C-MET mutation	Crizotinib 250 MG	Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.
Imatinib-CKIT mutation	Imatinib 400 MG	Administration: 400 mg oral qd, to disease progression or intolerable adverse effects.
Combination ARM-Niraparib & Sintilimab	Niraparib 200/300 MG	Niraparib (200mg oral qd) combined with Sintilimab (200mg iv q21d) after acquired resistance to Niraparib.
Combination ARM-Niraparib & Sintilimab	Sintilimab 100MG	Niraparib (200mg oral qd) combined with Sintilimab (200mg iv q21d) after acquired resistance to Niraparib.
Crizotinib-ROS-1 fusion	Crizotinib 250 MG	Administration: 250 mg oral bid, to disease progression or intolerable adverse effects.

Primary Outcome Measures

Name	Time	Method
Objective Response Rate (ORR)	Measured from first dose until confirmed response or progression, assessed up to 2 years.	The percentage of patients with a confirmed Blinded Independent Central Review (BICR) and investigator-assessed complete or partial response according to Response Evaluation Criteria In Solid Tumours (RECIST) 1.1.

Secondary Outcome Measures

Name	Time	Method
One year of Overall Survival rate (1-year OS rate)	Measured from first dose until death, assessed up to 2 years.	Percentage of patients who is alive at 1-year from first dose of treatment.
iRECIST Evaluated Progression Free Survival (iPFS)	Measured from response until progression, assessed up to 2 years.	The interval between the initiation of study treatment and the first documentation of CUPD (second confirmation of Disease Progression) or death due to any cause as defined by the iRECIST standard in the single drug immunotherapy group
Disease Control Rate (DCR)	Measured from first dose until confirmed response or progression, whichever came first, assessed up to 2 years.	The percentage of patients treated with targeted and single immunotherapy assessed by the investigator,
Overall survival (OS)	Measured from first dose until death or final cohort data cut-off, whichever came first, assessed up to 2 years.	The median survival time of patients
Incidence of Adverse Events (AE) in subjects	Continuously from first dose to end of safety follow up after study treatment discontinuation, assessed up to 2 years.	To evaluate safety and tolerability of each study treatment.
Progression-Free Survival (PFS)	Measured from first dose until progression, assessed up to 2 years.	The time from first dose until the date of objective disease progression or death (by any cause in the absence of progression).
Duration of Response (DoR)	Measured from response until progression, assessed up to 2 years.	The time from the date of first response until date of disease progression or death in the absence of disease progression.
Durable Clinical Benefit (DCB)	Measured from first dose until confirmed response or progression, whichever came first, assessed up to 2 years.	Partial Response (PR) or Complete Response (CR) or Stable Disease (SD) in the single drug immunotherapy group and without Disease Progression at more than six months.
The 6-month PFS rate	Measured from response until progression, assessed up to 2 years.	The proportion of patients who are alive and progression-free more than 6 months after the first dose of study therapy Progression-free Survival (PFS) the proportion of patients with PFS ≥ 6 months in the total enrollment since the start of the study.

Trial Locations

Locations (1)

Cancer hospital Chinese Academy of Medical Sciences; 🇨🇳 Beijing, China